What's new

Human medicines European public assessment report (EPAR): Evusheld, tixagevimab,cilgavimab, Date of authorisation: 25/03/2022, Revision: 9, Status: Authorised

Human medicines European public assessment report (EPAR): Evusheld, tixagevimab,cilgavimab, Date of authorisation: 25/03/2022, Revision: 9, Status: Authorised

Mar 12, 2025 - 16:56
 0
Human medicines European public assessment report (EPAR): Evusheld, tixagevimab,cilgavimab, Date of authorisation: 25/03/2022, Revision: 9, Status: Authorised
Human medicines European public assessment report (EPAR): Evusheld, tixagevimab,cilgavimab, Date of authorisation: 25/03/2022, Revision: 9, Status: Authorised
Read More

Tags:

Previous Article

IRIS guide for applicants - How to create and submit scientific applications, fo...

Next Article

UVM Health expands child care for employees

Related Posts

Orphan designation: xevinapant Treatment of ovarian cancer, 11/11/2015 Withdrawn

Orphan designation: xevinapant Treatment of ovarian can...

Feb 20, 2025  0

Herbal medicinal product: Urticae radix, Urtica dioica L.,Urtica urens L., F: Assessment finalised

Herbal medicinal product: Urticae radix, Urtica dioica ...

Mar 12, 2025  0

Human medicines European public assessment report (EPAR): Brimica Genuair, aclidinium,formoterol fumarate dihydrate, Date of authorisation: 19/11/2014, Revision: 16, Status: Authorised

Human medicines European public assessment report (EPAR...

Feb 25, 2025  0